Cite
HARVARD Citation
Puzanov, I. et al. (n.d.). 433 Talimogene laherparepvec (T-VEC) in combination with ipilimumab (IPI) versus IPI alone for advanced melanoma: 4-year interim analysis of a randomized, open-label, phase 2 trial. Journal for immunotherapy of cancer. pp. A263-A264. [Online].